BioSpace News Archive

Preparation of a Phase II program for THN101 in patients with neuropathic pain

Shares of Clovis Oncology are up more than 7 percent in premarket trading after the company announced positive results from a mid-stage clinical trial that showed patients treated with Rubraca achieved a 44 percent objective response rate in some patients with metastatic castration resistant prostate cancer (mCRPC).

Timicoin/TimiHealth announced a joint partnership with US HealthCenter and PredictiMed that is designed to focus on the capabilities of a blockchain tokenized hybrid rewards program.

The U.S. Bureau of Labor Statistics predicts a 7 percent increase in jobs for biomedical engineers and a 13 percent increase in medical scientists.

The trial was evaluating MM-121 in combination with docetaxel, a chemotherapy drug, in patients with heregulin positive non-small cell lung cancer (NSCLC).

The shareholders of Immunicum AB (publ) (the “Company”), reg. no 556629-1786, hereby summon to Extraordinary General Meeting on Thursday, 8 November 2018, at 14:30 p.m. at United Spaces, Östra Hamngatan 16, SE-411 Gothenburg, conference room Arenan. Registration for the meeting will commence at 14:00 p.m.

BC Platforms today announced it is launching its world leading genomics platform for HUS, the Hospital District of Helsinki and Uusimaa and the largest Healthcare service provider in the whole Nordics region.

NCRM & Edogawa Hospital to jointly award it as a part of NCRM NICHE in Tokyo, Japan

IRRAS AB announced today that, as of October 19, the IRRAS management consists of the following groups and persons:

44% confirmed objective response rate (ORR) reported in 25 RECIST-evaluable patients with a BRCA1/2 alteration in initial data from ongoing TRITON2 Phase 2 study; median duration of response has not yet been reached